HCG OBESITY ORAL :
Few substances have been so neglected and misunderstood regarding their potential therapeutic effects as hCG (Human Chorionic Gonadotropin). Secreted by the placenta, the presence of hCG in the urine of pregnant women was first reported by Ascheim and Zondek in 1927. Since then, thousands of articles have been published about the effect of hCG on gonads (testicles or ovaries), but comparatively a small number of these have investigated its vast therapeutic potential on diseases ranging from Kaposi sarcoma, to asthma, psychoses, artheriopaties, thalassemia, osteopenia, alcoholism, glaucoma.
HCG is one of the few drugs of natural origin that, fortunately, still remain in the current Pharmacopoeia. For unknown reasons, most of the research performed on its therapeutic potential deals with investigations related to testicles or ovaries, with comparatively few investigations performed in other clinical fields.
HCG proved to be effective in the above-mentioned conditions, but insufficient data were gathered to determine conclusively its clinical utility.
To complicate the situation even more, the use of hCG in the treatment of obesity has been the subject of controversy. The results of a series of studies were interpreted to mean that hCG should not be used for the treatment of obesity, notwithstanding reports that many patients that had been treated with the HCG protocol had been satisfied with the method and the obtained results.
Based on these opinions and the adherence to the method that I have observed in patients managed with HCG, I arrived at the conclusion that the effectiveness of hCG in the treatment of obesity merited further evaluation. Consequently, in 1991 I designed a research program intended to determine whether an oral formulation of hCG could be useful in the treatment of obesity.
The results of this study demonstrate that a formulation of oral hCG+ a Very Low Calorie Diet (VLCD) mobilizes fat from specific fat deposits more effectively than a Placebo+ VLCD diet treatment alone.
The study was performed on seventy obese volunteers using an entirely different approach to hCG administration : The oral route.
As Director of this Research Project, I firmly believe that experts in the field of obesity research would benefit by giving the method and this new approach a new, unbiased look. I also invite patients who have been treated with hCG to send their comments on the treatment or to post their comments in the Forum in this web site.
With obesity reaching epidemic proportions worldwide, it is now more important than ever to research effective procedures for its treatment.
After years of study, I have concluded that the effectiveness of hCG in the treatment of obesity has not been assessed fully. Negative side effects have thus been assigned to this substance that I sustain are incompatible with its nature and origin. For example, I have received e-mails from physicians and RNs who argue that hCG should not be used to treat obesity because of its side effects including, among others, hirsutism, and even cancer. Yet, large quantities of hCG (up to 1,000,000 IU per day) are secreted during pregnancy.
Therefore, based on this premise, women would be highly susceptible to cancer and excessive growth of hair during pregnancy. To my knowledge, there are no reports in the available medical literature of a higher susceptibility to hirsutism or cancer during pregnancy attributed to hCG secretion, or any reports that attribute such side effects to hCG administration
Based on approximately 20-years of experience in the treatment of obesity and obesity-related disorders, I have arrived at the conclusion that the hCG method for obesity treatment meets patients' expectations for a safe and effective weight loss program that is easy to follow and can improve their quality of life, without negative side effects or contraindications.
Dear visitors (physicians and the general public): You are welcome to browse this website, and send us your comments. I encourage a reasonable and scientific discussion on this issue.
